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A B S T R A C T
Background
Historically, oestrogen and progesterone were each commonly used to save threatened pregnancies. In the 1940s it was postulated that
their combined use would be synergistic and thereby led to the rationale of combined therapy for women who risked miscarriage.
Objectives
To determine the efficacy and safety of combined oestrogen and progesterone therapy to prevent miscarriage.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (23 June 2013) CENTRAL (OVID) (The Cochrane
Library 2013, Issue 6 of 12), MEDLINE (OVID) (1946 to June Week 2 2013), OLDMEDLINE (1946 to 1965), Embase (1974 to
Week 25 2013), Embase Classic (1947 to 1973), CINAHL (1994 to 23 June 2013) and reference lists of retrieved studies.
Selection criteria
We included randomised controlled trials that assessed the effectiveness of combined oestrogen and progesterone for preventing
miscarriage. We included one stratified randomised trial and one quasi-randomised trials. Cluster-randomised trials were eligible for
inclusion but none were identified. We excluded studies published only as abstracts.
We included studies that compared oestrogen and progesterone versus placebo or no intervention.
Data collection and analysis
Two review authors independently assessed trials for inclusion and assessed trial quality. Two review authors extracted data. Data were
checked for accuracy.
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Main results
Two trials (281 pregnancies and 282 fetuses) met our inclusion criteria. However, the two trials had significant clinical and method-
ological heterogeneity such that a meta-analysis combining trial data was considered inappropriate.
One trial (involving 161 pregnancies) was based on women with a history of diabetes. It showed no statistically significant difference
between using combined oestrogen and progestogen and using placebo for all our proposed primary outcomes, namely, miscarriage
(risk ratio (RR) 0.95, 95% confidence interval (CI) 0.32 to 2.80), perinatal death (RR 0.94, 95% CI 0.53 to 1.69) and preterm birth
(less than 34 weeks of gestation) (RR 0.91, 95% CI 0.80 to 1.04). In terms of this review’s secondary outcomes, use of combined
oestrogen and progestogen was associated with an increased risk of maternal cancer in the reproductive system (RR 6.65, 95% CI 1.56
to 28.29). However, for the outcome of cancer other than that of the reproductive system in mothers, there was no difference between
groups. Similarly, there were no differences between the combined oestrogen and progestogen group versus placebo for other secondary
outcomes reported: low birthweight of less than 2500 g, genital abnormalities in the offspring, abnormalities other than genital tract
in the offspring, cancer in the reproductive system in the offspring, or cancer other than of the reproductive system in the offspring.
The second study was based on pregnant women who had undergone in-vitro fertilisation (IVF). This study showed no difference in
the rate of miscarriage between the combined oestrogen and progesterone group and the no treatment group (RR 0.66, 95% CI 0.23
to 1.85). The study did not report on this review’s other primary outcomes (perinatal death or rates of preterm birth), nor on any of
our proposed secondary outcomes.
Authors’ conclusions
There is an insufficient evidence from randomised controlled trials to assess the use of combined oestrogen and progesterone for
preventing miscarriages. We strongly recommend further research in this area.
P L A I N L A N G U A G E S U M M A R Y
Combined use of oestrogen and progesterone for preventing miscarriage
The hormones oestrogen and progesterone have established physiological roles in maintaining pregnancy. It has been suggested that
supplementation of these hormones could help prevent miscarriage before 24 weeks of pregnancy, particularly in women who have low
levels of the hormones, in assisted reproductive technology programs, or who have a history of repeated miscarriages. In our review of
randomised controlled trials published in major scientific databases, we only identified two trials that met our inclusion criteria. The two
trials involved small numbers of women. One involved 161 women with diabetes who took oral placebo or oral diethylstilboestrol and
ethisterone in increasing doses from before the end of the 16th week until birth. The other trial involved 120 women with pregnancy
assisted by in vitro fertilisation and embryo transfer who continued treatment until the completed 12th week of gestation.
From the little evidence available, the two trials found no evidence that combined oestrogen and progestogen can prevent miscarriage
(progestogen is a major class of hormones which includes progesterone) when compared with placebo or usual care. The first of the
two studies indicated an increased risk for the mothers who used hormonal therapy during pregnancy of developing cancer later in life.
Diethylstilboestrol is no longer in use and poses serious adverse effects while ethisterone contains androgenic properties thought to be
responsible for genital abnormalities and has been replaced by progesterone.
Overall, we acknowledge the lack of trials, especially large-scale trials, and therefore suggest further research is needed in this area before
supporting or disproving the use of combined oestrogen and progesterone for the prevention of miscarriages.
B A C K G R O U N D
Description of the condition
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Definitions
Miscarriage, or ’spontaneous abortion’, is defined as the loss of
pregnancy under 24 weeks of gestation (RCOG 2006). ’Recur-
rent miscarriage’ is defined as having three or more consecutive
spontaneous miscarriages (RCOG 2003). Pregnant women may
undergo ’threatened miscarriage’, which presents as vaginal bleed-
ing, with or without pain, within the first 20 weeks of pregnancy
(Cunningham 2010). A closed cervix helps keep the fetus viable
inside the uterine cavity. Once cervical dilatation occurs, a mis-
carriage is deemed as ’inevitable’ (Cunningham 2010).
Incidence
Miscarriage is common and occurs in 10% to 15% of all clini-
cally recognised pregnancies (Everett 1997; Liu 1991; Regan 1989;
Stirrat 1990; Warburton 1964). Furthermore, an even higher mis-
carriage rate of 31% has been reported when undetected preg-
nancies are considered (Wilcox 1988). Threatened miscarriage has
been reported to be present in 20% to 25% of pregnant women
(Cunningham 2010; Everett 1997). Around 1% of all women suf-
fer from recurrent miscarriage and, given that this incidence rate is
higher than that expected by chance, a proportion of women with
recurrent miscarriage will have particular aetiologies underlying
their miscarriages (RCOG 2003).
Impact
The miscarriage process may be a traumatic event for women both
physically and psychologically. Physical impact may involve sud-
den, considerable pain, blood loss, rapid hospitalisation and oper-
ation (Lee 1996). Furthermore, the operative process such as di-
latation and curettage is known to be associated with - other than
surgical risks - stress and emotional responses (Lee 1996). After
miscarrying, the psychological impact may also include depressive
symptoms, anxiety and development of obsessive-compulsive dis-
order. Such decline in mental health can last up to six months or
more after miscarrying (Janssen 1996).
Pathophysiology
The process of miscarriage initiates within a few weeks after the
death of the embryo. Haemorrhage in the decidua basalis, which is
the endometrial area that forms the base of the implanted site, to-
gether with adjacent tissue necrosis and inflammation, lead to de-
tachment of the gestational sac and implanted ovum. The detach-
ment stimulates uterine contractions and cervical dilation, subse-
quently resulting in expulsion (Porter 2008).
Aetiology
Spontaneous miscarriage
Despite numerous theories, there remains a large number of mis-
carriage cases in which an exact cause cannot be identified. Ultra-
sonography and histological investigations from cases of sponta-
neous miscarriages show that 70% is related to a defective ovum or
fetus, the most common cause being chromosomal abnormalities
(Oats 2010). In fact, chromosomal abnormalities have been re-
ported to account for more than 50% of all miscarriages (Burgoyne
1991; Goddijin 2000; Simpson 2007). Other causes which are less
common include defective implantation, systemic maternal dis-
ease (such as poorly-controlled insulin-dependent diabetes) (Mills
1988), uterine abnormalities and possibly psychosomatic causes,
although the latter have been difficult to evaluate in studies (Oats
2010). Maternal infections are an uncommon cause (Cunningham
2010). There are many risk factors which are associated with a
higher incidence of miscarriage: maternal age of greater than 35
years, previous history of miscarriage (Garcia-Enguidanos 2002;
Walch 2008), smoking, alcohol use, high caffeine use and expo-
sure to certain environmental toxins (Cunningham 2010).
Recurrent miscarriage
The known aetiologies are similar to the causes described for spon-
taneous miscarriage; however there is some difference in terms
of their occurrence. For instance, chromosomal abnormalities be-
come a less likely cause for recurrent miscarriage, while uterine
malformations, particularly cervical incompetence, are more likely
(Oats 2010). Other aetiologies include predisposing conditions
to thrombosis (such as antiphospholipid syndrome and throm-
bophilia), endocrinological factors (such as polycystic ovaries, thy-
roid dysfunction) and immunological factors (such as systemic lu-
pus erythematosus) (Carrington 2005; Li 2002; Toth 2010). De-
spite all this, around 50% of recurrent miscarriages remain unex-
plained (Habayeb 2004; Tulppala 1993).
Description of the intervention
Progesterone and oestrogen are both female sex hormones which
are essential in the maintenance of pregnancy. Progesterone is pro-
duced from the ovary by the corpus luteum after ovulation. While
the corpus luteum continues progesterone synthesis up to the 10th
week of gestation (Speroff 2005), the placenta concurrently begins
to synthesise progesterone and by the 12th week, enough proges-
terone is produced to replace the corpus luteum source (Genuth
2006). Progesterone is responsible for multiple functions in the
pregnancy - see How the intervention might work - and the insuf-
ficiency of progesterone during the luteal phase of the menstrual
cycle and during early pregnancy are thought to be one of the
many causes of miscarriage (Haas 2008). For this reason, women
who have low progesterone levels of 10 ng/mL or less during early
pregnancy may be supplemented with 100 mg progesterone daily
until the 10th week (Speroff 2005). Women who use assisted re-
productive technology may also require progesterone use before
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pregnancy, during the luteal phase of their menstrual cycle as a
means of preparing the endometrium for successful implantation
(Balasch 1987).
Similarly, progestogen has also been used in cases of assisted re-
productive technology (Abu-Musa 1998; Daya 2009) and in pre-
vention of miscarriages (Hemminki 1999; Johnson 1979), includ-
ing threatened cases (Duan 2010; Thierstein 1959). One of the
main concerns about maternal progestogen use has been the ad-
verse effect of genital tract abnormalities presenting in newborns
who were exposed in utero (Silver 1999; Wilkins 1960), but the
association with malformations may be weak (Kullander 1976).
The second element of the intervention is oestrogen, another hor-
mone produced from the ovaries. Historically, it was proposed that
diethylstilboestrol, a synthetic oestrogen which enhanced both oe-
strogen and progesterone secretion, could combat the problem of
hormonal deficiency in pregnancy, thereby acting as a therapeutic
agent for preventing miscarriages, and perhaps hinder or lessen
the impact of adverse pregnancy outcomes, such as eclampsia and
preterm delivery (Smith 1948).
However, from the 1970s onwards, some adverse effects were
identified in offspring who were exposed to diethylstilboestrol
in utero, leading to the declaration of its contraindicated use in
pregnancy by the US Food and Drug Administration in 1971
(FDA 1971). Adverse effects included premature birth and geni-
tal tract abnormalities in both male and female offspring (Bibbo
1977; Herbst 1971; Palmer 2005). For female offspring, estab-
lished and documented effects include cervical adenocarcinoma
(Herbst 1981), vaginal adenocarcinoma (Herbst 1971) and vaginal
adenosis (Bibbo 1977; Herbst 1971). Amongst the lesser known
adverse effects, one 1977 follow-up study of prenatally exposed
offspring from the early 1950s reported abnormalities, namely,
irregular menstrual cycle and lower incidence of pregnancy in fe-
male offspring; and in male offspring, increased cases of pathologic
semen (Bibbo 1977). Other sources describe poorer pregnancy
outcomes for females exposed in utero; specifically higher rates
of ectopic pregnancies, miscarriages and preterm births (Barnes
1980; Berger 1980; Goldberg 1999). Increased risk of infertility
in female offspring (Palmer 2005) and slightly increased risk in
males (Perez 2005) have also been postulated, while other authors
have dismissed an increased risk of infertility when exposed to oe-
strogen or progestins (Hemminki 1999).
In recent decades, scientific literature has typically described the
combined use of oestrogen and progesterone in the context of as-
sisted reproductive technologies, in particular in-vitro fertilisation
(IVF), by which if the woman achieves pregnancy, hormonal sup-
plementation would be continued throughout the early pregnancy
period, or until the placenta has assumed the role of hormonal
production (Davar 2007; Devroey 1998; Lelaidier 1992; Muasher
1991; Navot 1986; Queenan 1997; Schindler 2005). Despite the
varying results over which drug protocol is best for luteal support,
this review will only include trials which compare combined oe-
strogen and progesterone versus placebo or no intervention, where
the comparison is undertaken during, but not limited to, the time
of pregnancy. We also aim to clarify the effect of such therapy on
preterm birth since there are both therapeutic claims and claims
of preterm birth as an adverse effect from therapy.
How the intervention might work
The established roles of oestrogen and progesterone have been
known to be beneficial towards maintenance of pregnancy. First,
progesterone can stimulate secretory changes in the endometrial
layer of the uterus, in order to create a stabilised surface for the
fertilised egg to implant upon (Duan 2010; Potdar 2005). Sec-
ond, progesterone keeps the myometrial layer of the uterus quies-
cent; that is, suppresses the uterus from contracting, which again is
important for stable implantation, and important for preventing
preterm labour later on in pregnancy (Duan 2010; Rao 1998).
Third, progesterone is a potent modulator working in the mater-
nal immune system to prevent the rejection of the fetus as foreign
tissue (Genuth 2006; Schorge 2008; Walch 2008). By these var-
ious physiological functions, progesterone supplementation and
its effects are assumed to be beneficial for pregnancy.
Oestrogen induces proliferation of the endometrial layer, which
also helps to prepare for successful implantation (Genuth 2006).
In addition, oestrogen stimulates continuous growth of uterine
muscles (Bengtsson 1973) and influences blood flow to the uterus
(Genuth 2006), all of which aim to accommodate for pregnancy.
Another feature of oestrogen is the ability to increase synthesis
of oestrogen receptors and progesterone receptors. This enables
oestrogen to amplify its own effects on uterine growth as well as
enhancing the effects of progesterone (Genuth 2006).
Why it is important to do this review
Related reviews and protocols evaluating the efficacy of hormone
administration for miscarriage prevention are already available in
The Cochrane Library.
• Oestrogen supplementation, mainly diethylstilbestrol, for
preventing miscarriages and other adverse pregnancy outcomes
(Bamigboye 2003)
• Progestogen for preventing miscarriage (Haas 2008)
• Progestogen for treating threatened miscarriage (Wahabi
2011)
The above Cochrane reviews have only addressed the evidence of
these two hormones separately, and not in combination. In all
three reviews, any combination therapy used in a randomised con-
trolled trial (RCT) resulted in the exclusion of that RCT from
their analyses. However, given that for decades, both oestrogen
and progesterone have been viewed as essential hormones support-
ive of pregnancy and given that the added presence of oestrogen
can amplify the effects of progesterone (Genuth 2006), it would
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therefore be important to formally examine the evidence to sup-
port the efficacy of such combined use.
O B J E C T I V E S
To determine the efficacy and safety of combined oestrogen and
progesterone as preventative therapy against miscarriage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials that assessed the effec-
tiveness of combined oestrogen and progesterone for preventing
miscarriage. We included one stratified randomised trial and one
quasi-randomised trial. Cluster-randomised trials were eligible for
inclusion but none were identified. We excluded studies published
only as abstracts.
Types of participants
We included all pregnant women, but in order for results to be
meaningful in terms of clinical applicability, we categorised par-
ticipants according to particular clinical conditions or particular
risk factors in the subgroup analysis - see Subgroup analysis and
investigation of heterogeneity.
Types of interventions
We compared oestrogen and progesterone versus placebo or no
intervention. We also included studies which used a progesto-
gen different to progesterone, due to its historic relevance and
use in assisted reproductive technology - see Description of the
intervention. However, because of differences in chemistry, we had
to view other progestogens as a separate intervention from proges-
terone. Hence, we presented data on the first two comparisons.
• Combined oestrogen and progestogen (other than
progesterone) versus placebo
• Combined oestrogen and progesterone versus no hormonal
treatment
• Combined oestrogen and any progestogen versus placebo or
no hormonal treatment
We do not exclude the possibilities of other comparisons arising
from future updates of this review.
Studies that compare therapy with no treatment rather than with
placebo have more potential for bias. This potential for bias has
been addressed in the review by analysing the placebo-based trial
and no-treatment-based trial both separately and in conjunction.
Types of outcome measures




3. Preterm birth (less than 34 weeks of gestation)
Secondary outcomes
Offspring
1. Low birthweight of less than 2500 g
2. Genital tract abnormalities
3. Abnormalities other than of the genital tract
4. Cancer in the reproductive system
5. Cancer other than of the reproductive system
Mother
1. Cancer in the reproductive system
2. Cancer other than of the reproductive system
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (23 June
2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
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within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we searched CENTRAL (OVID) (The Cochrane Li-
brary 2013, Issue 6 of 12), MEDLINE (OVID) (1946 to June
Week 2 2013), OLDMEDLINE (1946 to 1965), Embase (1974
to Week 25 2013), Embase Classic (1947 to 1973) and CINAHL
(1994 to 23 June 2013). See Appendix 1; Appendix 2; Appendix
3; Appendix 4; Appendix 5; and Appendix 6 for search strategies.
Searching other resources
We also scanned through studies referenced in three related
Cochrane reviews (Bamigboye 2003; Haas 2008; Wahabi 2011)
and other retrieved studies.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion all po-
tential studies identified as a result of the search strategy. We re-
solved any disagreement through discussion. We did not require
any consultation with a third party, although if in the future, dur-
ing the process of updating this review, there is disagreement that
is unable to be resolved between the two review authors, we will
maintain the strategy of consulting a third party.
Data extraction and management
We designed a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved dis-
crepancies through discussion. We did not require any consulta-
tion with a third party, but shall maintain this strategy if required
when conducting future updates. We entered data into Review
Manager software (RevMan 2012) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion. We did not require consultation
with a third party, but shall maintain this strategy if required when
conducting future updates.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determine whether intervention allo-
cation could have been foreseen in advance of, or during recruit-
ment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
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(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or supplied by the trial
authors, we re-included missing data in the analyses which we un-
dertook. We assessed methods as:
• low risk of bias (where less than 20% of the randomised
population was excluded);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias
We described for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias and whether we considered it is likely to im-
pact on the findings. We explored the impact of the level of bias
through undertaking sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
No continuous data were used. However, for the purpose of future
updates, we maintain the strategy of using the mean difference if
outcomes are measured in the same way between trials. If appro-
priate in future updates of this review, we will use the standardised
mean difference to combine trials that measure the same outcome,
but use different methods.
Unit of analysis issues
Cluster-randomised trials
No cluster-randomised trials were included in this version of the
review. However, in future updates of the review, we will include
cluster-randomised trials in the analyses along with individually-
randomised trials. We will adjust their sample sizes using the meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) using an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
We excluded cross-over trials due to concerns over order effects
and carry-over effects related to our proposed outcomes of interest.
In one study (MRC 1955), a minority of the randomised popula-
tion proved to be cross-over participants. We intended to collect
individual participant data as far as possible, to utilise the results
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from the first period of the cross-over only. However, the individ-
ual data in this minority group were unavailable, and hence we
reported ’unclear risk’ under the category ’other potential sources
of bias’.
Other unit of analysis issues
Multiple pregnancies
For trials involving multiple pregnancies, we undertook methods
described in Cochrane Pregnancy and Childbirth Group Method-
ological Guidelines accordingly (Gates 2009). One trial involved
one set of twins in their data, which was not substantial within the
randomised population, but nonetheless we analysed the fetuses as
if independent and used the number of fetuses as the denominator
according to Cochrane Pregnancy and Childbirth Group Method-
ological Guidelines accordingly (Gates 2009) and to our protocol.
For the purpose of future updates, we will maintain the same strat-
egy if it is not possible to make adjustments for the multiple preg-
nancies due to unavailable information.
Dealing with missing data
For included studies, we noted the levels of attrition. We explored
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses, and analysed all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes were known to
be missing in an unbiased manner.
We excluded from the analyses data from trials or outcomes that
were at high risk of bias, e.g. those with high levels of missing data
or a large number of participants analysed in the wrong group.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the I² was greater than 30% and either the T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more studies
in the meta-analysis, we will investigate reporting biases (such as
publication bias) using funnel plots. We will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
In future updates of this review, we will carry out statistical analy-
ses using the Review Manager software (RevMan 2012). We will
use fixed-effect meta-analysis for combining data where it is rea-
sonable to assume that studies are estimating the same underly-
ing treatment effect: i.e. where trials are examining the same in-
tervention, and the trials’ populations and methods are judged
sufficiently similar. If there is clinical heterogeneity sufficient to
expect that the underlying treatment effects differ between trials,
or if substantial statistical heterogeneity is detected, we will use
random-effects meta-analysis to produce an overall summary if an
average treatment effect across trials is considered clinically mean-
ingful. We will treat the random-effects summary as the average
range of possible treatment effects and we will discuss the clinical
implications of treatment effects differing between trials. If the
average treatment effect is not clinically meaningful, we will not
combine trials.
If we use random-effects analyses, we will present the results as the
average treatment effect with its 95% confidence interval, and the
estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We did not carry out subgroup analyses given the substantial het-
erogeneity between the two included studies. For the purpose of
future updates, we will maintain the strategy of carrying out for-
mal subgroup analysis for the following subsets, if required.
1. Women with threatened miscarriage versus women without
threatened miscarriage.
2. Women with recurrent miscarriage versus women without
recurrent miscarriage.
3. Women using IVF versus women without IVF treatment.
We will analyse each subgroup in relation to each of the primary
outcomes - see Primary outcomes.
We will consider whether an overall summary is meaningful, and
if it is, use random-effects analysis to produce it.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2012). We will report the results of
subgroup analyses quoting the χ2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
We will conduct sensitivity analyses to investigate the following
effects on primary outcomes.
1. Inclusion/exclusion of trials with ’no intervention’ as the
control group.
2. Inclusion/exclusion of trials at high risk of bias, as
determined the risk of allocation concealment.
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3. Variations in the analysis of trial types stated in Unit of
analysis issues.
4. Inclusion/exclusion of trials with high levels of missing data.
5. Fixed-effect/random-effects analyses for outcomes with
statistical heterogeneity.
R E S U L T S
Description of studies
See: Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
We retrieved four reports of two studies from the search of the
Pregnancy and Childbirth Group’s Trials Register, three reports
for MRC 1955 and one from Prietl 1992). These two studies were
included in our analysis.
The total number of ’hits’ from searching databases was 960; nine
from CENTRAL; 365 from MEDLINE; 31 from OLDMED-
LINE; 470 from Embase; 20 from Embase Classic; and 65 from
CINAHL. Of the 960 hits, 906 were immediately excluded due to
duplicated hits of the exact same study or due to irrelevance to our
research topic. We could not obtain the full texts or translations
of 54 results despite our access to 12 international library systems.
We postulate that this is due to the fact that the articles were pub-
lished some time ago and the lack of access to non-English titles,
evident by the fact that 52 of 54 were non-English language pa-
pers. Therefore, our list of potentially relevant studies was five.
Of the five studies, four studies were assessed and classified as
excluded studies - see Excluded studies - and the remaining study
was assessed and classified as an included study. In addition, we
scanned the references of significant reports, which resulted in one
extra study. This extra study produced two reports, one report for
its original study and another report for its follow-up results of the
same cohort. Hence in total, two studies were classified as included
studies - see Included studies.
Included studies
Two trials were included, involving 281 pregnancies and 282 fe-
tuses. One trial, MRC 1955, subsequently had two follow-up stud-
ies performed 27 years after, on mothers and offspring respectively.
The follow-up studies involved 156 mothers and 136 children.
The MRC 1955 study was conducted across nine centres. One-
hundred and sixty-one pregnancies from 156 women were ran-
domised by simple stratification, however 147 were included in
their analysis - see Incomplete outcome data (attrition bias). Of
the 147 pregnancies, one set of twins was included hence there
were 148 fetuses. All analysed participants were pregnant women
under 16 weeks’ gestation with a background of diabetes mellitus
(duration of diabetes averaged around eight years in both groups).
Participants were allocated to either oral placebo or oral diethylstil-
boestrol and ethisterone. Diethylstilboestrol and ethisterone were
started at 50 mg/day and 25 mg/day before the end of the 16th
week then the dosage increased every three weeks until birth, by
which time dosage was 200 mg/day and 250 mg/day respectively
-see Characteristics of included studies for detailed dose regimen.
For the offspring, the outcomes of interest included were miscar-
riage, stillbirth, neonatal death, time of delivery and birthweight.
For the mother, the outcomes included maternal death and pre-
eclampsia.
The same 156 women were followed up in the MRC 1955 study,
however 151 were included in their analysis - see Incomplete
outcome data (attrition bias). The mothers were not contacted
directly. Instead, data were collected from their general practition-
ers, from hospital and diabetic clinics, and from Office of Pop-
ulation Censuses and Surveys. General practitioners were asked
to complete questionnaires, which included questions about the
occurrence of cancer. Outcomes of interest included death, cancer
in the reproductive sites and cancers in other sites.
Twelve miscarriages occurred in the 148 fetuses in the MRC 1955
study, thus 136 offspring were included in the follow-up study.
This group included data from stillbirths and neonatal deaths.
Five were excluded. Children were not contacted directly and all
methodology was identical to that described for the follow-up
study of the mothers. Outcomes of interest included death under
and over the age of one, urogenital abnormalities, other abnor-
malities, cancers, number of those who consulted for infertility,
number of those married with history of miscarriage, and number
of those married with at least one child. However, data for the
latter three outcomes were not used in our analyses and we explain
why - see Incomplete outcome data (attrition bias).
The second included trial, Prietl 1992, was a quasi-randomised
trial involving 120 pregnancies assisted by in vitro fertilisation
and embryo transfer (IVF-ET). Two participants were excluded.
Women were ensured of normal endocrine profiles before IVF
treatment. Despite different IVF protocols used before pregnancy,
a balanced baseline in protocol types was achieved between the
intervention and control group. After confirmation of pregnancy,
participants were randomised, according to their odd or even year
of birth, to either intramuscular injection of 500 mg 17α-hydrox-
yprogesterone caproate and 10 mg oestradiol valerate in an oily
vehicle (Gravibinon) twice a week, or, to no hormonal treatment.
Treatment continued until the completed 12th week of gestation.
The only outcome of interest was miscarriage.
Excluded studies
We excluded four studies (Berle 1977; Crowder 1950; Lightman
1999; Sathanandan 1991). An explanation for exclusion of each
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study is provided - see Characteristics of excluded studies.
Risk of bias in included studies
See: Figure 1 for a summary of risk of bias assessed in our in-
cluded studies. For detailed descriptions of each risk of bias, see
Characteristics of included studies.
Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation and allocation concealment was ad-
equate in one study (MRC 1955) and inadequate in the other
(Prietl 1992).
Blinding
In MRC 1955, blinding of both patients and personnel was ad-
equate. Blinding continued throughout follow-up period. In the
other study, Prietl 1992, there was no placebo use and the sequence
was known to personnel, thus blinding was deemed inadequate.
Incomplete outcome data
The MRC 1955 study performed randomisation before assess-
ment for eligibility. After assessment for eligibility, there were 14
exclusions (10 control, four treated) of which eight were reason-
ably excluded, due to non-pregnancies and miscarriage prior to
intervention use. Of the remaining six, two had advanced beyond
the age of 16 weeks, which still meets our review criteria, but not
the criteria set by the original study and hence excluded in the
original study. Finally, four were avoidable exclusions quoted to
have “lacked cooperation or some other complication supervened”
(MRC 1955). Given this, the latter six would have been ideally in-
cluded in our analyses on the basis of intention-to-treat, however
the intervention to which these six participants were allocated to
was unknown. Despite this, attrition bias remains low because 14
exclusions out of 161 participants is only 8.7%.
Only two exclusions eventuated from Prietl 1992 due to ectopic
pregnancy (one control, one treated). These are unavoidable ex-
clusions, which remain excluded in our analyses.
The overall low levels of missing data in both studies deem low risk
in attrition bias. For further details - see Risk of bias in included
studies.
Selective reporting
In both studies, all pre-specified outcomes were reported, hence
we assessed both studies as being free from selective reporting bias.
Other potential sources of bias
Cross-over participants
One study, MRC 1955, was inadequate for this risk of bias due
to five cross-over participants accounting for 10 pregnancies. This
is not without concern of order effects and carry-over effects, and
ideally, only data from the first period of the cross-over would
be used in our analyses, however due to unavailable individual
data, we cannot achieve this. Despite everything, we are reminded
that the inclusion of five pregnancies from a second period cross-
over represents only 3.12% of the randomised population. We
proceeded to include these data, but assessed the trial as ’unclear’
under ’other bias’.
Effects of interventions
Justification of why meta-analysis was not performed
Two trials met our inclusion criteria (MRC 1955; Prietl 1992).
We extracted data from MRC 1955 for all three of our primary
outcomes and seven of secondary outcomes. From Prietl 1992,
only one primary outcome was measured. This single common
primary outcome was miscarriage. We decided that the pooling of
results from both trials for this common outcome was inappropri-
ate as there is obvious clinical and methodological heterogeneity
between the two trials.
1. One trial was on women with long histories of diabetes
(MRC 1955), the other was conducted in the context of
pregnant women who had undergone IVF treatment on various
protocols (Prietl 1992).
2. Average age of the women differed approximately 10 years.
3. Intervention used differed in type, dosage, mode of
administration, timing of use in pregnancy, and the type of
control was different.
4. Definition of miscarriage was different.
5. Trial design was different.
6. The way trials were conducted differed in terms of
allocation concealment and blinding.
Comparison 1 - Combined oestrogen and
progestogen (other than progesterone) versus
placebo (in women with history of diabetes)
Primary outcomes
In one trial of 148 women (MRC 1955), miscarriage was not sig-
nificantly different between the combined hormonal and placebo
groups (risk ratio (RR) of 0.95, 95% confidence interval (CI) 0.32
to 2.80) - Analysis 1.1. Other primary outcomes had similar re-
sults: perinatal death (RR 0.94, 95% CI 0.53 to 1.69 - Analysis
1.2) and preterm birth less than 34 weeks (RR 0.91, 95% CI 0.80
to 1.04 - Analysis 1.3).
Secondary outcomes
For the offspring
Secondary outcomes for the offspring revealed no statistical signif-
icance between groups: low birthweight of less than 2500 g (RR
0.87, 95% CI 0.43 to 1.77 - Analysis 1.4); genital tract abnor-
malities (RR 1.57, 95% CI 0.60 to 4.08 - Analysis 1.5); abnor-
malities other than of the genital tract (RR 0.42, 95% CI 0.14 to
11Combined oestrogen and progesterone for preventing miscarriage (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.30 - Analysis 1.6); cancer in the reproductive system of offspring
(RR 2.83, 95% CI 0.12 to 68.29 - Analysis 1.7) and cancer other
than of the reproductive system (RR 2.83, 95% CI 0.12 to 68.29
- Analysis 1.8). All of these long-term secondary outcomes were
recorded 27 years after the original study.
Maternal outcomes
Amongst the outcomes for the mother, the rate of cancer in the
reproductive system was statistically significant (RR 6.65, 95% CI
1.56 to 28.29 - Analysis 1.9). In other words, our findings suggest
that maternal hormone use is associated with an increased risk
of having cancer in a reproductive site 27 years later by 565%.
Cancer other than of the reproductive system in mothers was not
statistically significant (RR 1.90, 95% CI 0.36 to 10.07 - Analysis
1.10).
Comparison 2 - Combined oestrogen and
progesterone versus no hormonal treatment (in
pregnant women having undergone IVF treatment)
Primary outcomes
For a single trial of 118 women (Prietl 1992), the only available
outcome reported was miscarriage (RR 0.66, 95% CI 0.23 to 1.85)
and there was no statistical difference between groups - Analysis
2.1.
Secondary outcomes
None of our pre-specified secondary outcomes were reported in
the Prietl 1992 trial.
D I S C U S S I O N
Summary of main results
Two trials were included in our systematic review on the maternal
use of combined oestrogen and progesterone. Both trials were re-
garded separately due to clinical and methodological heterogene-
ity.
One trial MRC 1955 compared combined oestrogen and pro-
gestogen versus placebo in mothers with a history of diabetes.
There was no statistical difference for the following outcomes:
miscarriage, perinatal death, preterm birth and low birthweight.
In the follow-up study, which was conducted 27 years later, there
was no statistical difference for the following outcomes: genital
abnormalities in offspring, abnormalities other than of the genital
tract in offspring, cancer of the reproductive system in offspring,
cancer other than of the reproductive system in offspring, cancer
other than of the reproductive system in mothers. There was how-
ever, a statistical difference in cancer of the reproductive system of
mothers 27 years later by 565% (RR 6.65, 95% CI 1.56 to 28.29
- Analysis 1.9).
The other trial Prietl 1992 compared combined oestrogen and
progesterone versus no hormonal treatment in pregnant women
who had undergone IVF treatment. There was no statistical dif-
ference for the outcome of miscarriage. Other outcomes were not
measured in this trial.
Overall completeness and applicability of
evidence
To the best of our knowledge, this is the only systematic review
on the maternal use of combined oestrogen and progesterone for
preventing miscarriage. Very little on this topic was identified,
with only two trials meeting our inclusion criteria. Both trials
recruited small numbers of women, the pooling of which was
deemed inappropriate. Therefore, there is insufficient evidence
overall.
In terms of outcomes, most of our data for the pre-specified out-
comes derived from one of the two studies, MRC 1955, whereas
the other study, Prietl 1992, only addressed one of our outcomes.
Therefore, more evidence is needed in order to address other out-
comes.
We question the clinical applicability of the MRC 1955 due
to its interventions diethylstilboestrol and ethisterone. Diethyl-
stilboestrol is no longer in use and poses serious adverse effects
(Bamigboye 2003) while ethisterone contains androgenic prop-
erties thought to be responsible for genital abnormalities, hence
has been commonly substituted by progesterone in modern times
(Abu-Musa 1998; Sullivan 1986).
Quality of the evidence
One of the two included studies, Prietl 1992, is at high risk of
bias - see Figure 1 - with its alternation sequence generation thus
inadequacy in allocation concealment and lack of placebo, thus
performance bias.
Potential biases in the review process
We could not obtain the full texts or translations of 55 results
despite our access to 12 international library systems. We postulate
that this is due to the age of the articles and the lack of access to
non-English titles, evident by the fact that 53 of 55 were non-
English language papers.
There are no other potential biases.
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Agreements and disagreements with other
studies or reviews
The authors of MRC 1955 and Prietl 1992 could not support the
benefit of hormone treatment for the prevention of miscarriages
(as defined by their own definition), however Prietl 1992 claimed
that the significantly higher rate of preclinical pregnancies in their
control group, which towards the end resulted in significantly
lower ongoing pregnancy rate reflected the ability of hormone
treatment in salvaging early pregnancies. This claim however, lacks
support from other IVF studies of the non-randomised type. These
studies involved comparison of natural cycle IVF and programmed
hormone cycle IVF, and the latter intervention always implied
continuous hormone support throughout early pregnancy. Three
such studies were identified, of which two had dealt with very small
numbers (de Ziegler 1990; Schmidt 1989) and the third, a large
retrospective study (Queenan 1994) showed almost identical rates
in pregnancies, clinical pregnancy losses and ongoing pregnancies.
Studies not dealing with IVF similarly refuted the hypothesis of
better salvage rates with hormonal therapy (Crowder 1950; Nesbitt
1965).
In our analyses, the only outcome that showed statistical signifi-
cance was the higher rate of cancer in reproductive sites of treated
mothers. Our data for this outcome derived from the follow-up
study of MRC 1955, and the authors of MRC 1955 investigated
for a possible dose-response relationship between the total amount
of diethylstilboestrol taken during pregnancy and the occurrence
of such cancers (there was no explanation of why the authors called
it ’diethylstilboestrol dose-response’ when presumably combined
diethylstilbostrol and ethisterone were given). Nonetheless, a con-
vincing dose-response relationship was not established. A 25-year
follow-up study focusing on mothers who were exposed to diethyl-
stilboestrol only (Bibbo 1978) followed up a much larger popu-
lation but its original trial involved lower amounts of diethylstil-
boestrol exposure than MRC 1955. When we interpreted the data
from Bibbo 1978 we found that, in contrast to our findings, there
was no significant difference in reproductive site cancers between
exposed and unexposed mothers. Hence, the relationship between
hormonal exposure during pregnancy and rate of cancer in repro-
ductive sites remains a gap in research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to assess the effectiveness and safety
of the maternal use of combined oestrogen and progesterone for
the prevention of miscarriage. One small study suggests that com-
bined hormonal use was associated with increased risk of repro-
ductive cancer for the mother, however, this increased risk could
not be supported by evidence in other scientific trials. We conclude
that more research is needed prior to establishing any implications
for practice.
Implications for research
There is an insufficient number of trials to support or refute the
use of combined oestrogen and progesterone in preventing mis-
carriages. Ideally, trials should recruit a large number of partic-
ipants, use randomised allocation, use placebo, remain blinded,
minimise drop-out rates and report the results of all pre-specified
outcomes. For information of some of the secondary outcomes,
we recommend that a follow-up study of original participants and
their offspring be conducted in the long term.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
MRC 1955
Methods Simple, stratified randomisation in a multicentre trial. Stratified by age and parity
Timing of randomisation: occurred before assessment for eligibility
Baseline characteristics in each intervention group were established and made comparable
Participants From across 9 centres, 161 pregnancies of women with diabetes in their 16th week of
gestation or less were randomised. 14 were excluded (8 not pregnant prior to interven-
tion use, 2 whose gestational age surpassed their ’16 weeks or less’ criteria, 4 “lacked
cooperation or some other complication supervened”). Remaining 147 were analysed
(71 control, 76 intervention)
Age: all participants were aged 40 or below. Treatment group mean age was 22.4. Control
group mean age was 20.4
Country: UK.
Date of study: July 1950 to January 1953.
Interventions Control: placebo tablets identical to intervention.
Intervention: oral diethylstilboestrol (Stilbestrol) and ethisterone in increasing doses
Dosage and duration: (in mg/day)
• Before the end of 16th week - end of 19th week: 50 diethylstilboestrol, 25
ethisterone.
• 20th - 23rd weeks inclusive: 100 diethylstilboestrol, 50 ethisterone.
• 24th - 27th weeks inclusive: 100 diethylstilboestrol, 75 ethisterone.
• 28th - 31st weeks inclusive: 150 diethylstilboestrol, 125 ethisterone.
• 32nd week - delivery: 200 diethylstilboestrol, 250 ethisterone.
Outcomes Miscarriage (defined as fetal death before 28 weeks of gestation)
Stillbirth (defined as expulsion after 28 weeks’ gestation without breath or showing any
signs of life)
Neonatal death (defined as death after showing signs of life)
Living children (defined as children surviving for at least 1 month. This group was
followed up for at least 6 months)
Maternal death.
Preterm birth (not defined, but delivery times were tabulated by week of delivery)
Birthweight (not defined, but weights were tabulated by whole pounds)
Congenital abnormalities (not defined).
Pregnancy complications: oedema, albuminuria, toxaemia and hydramnios
Outcomes from follow-up study on mothers
Death in later life.
Cancer in the reproductive system.
Cancer other than of the reproductive system.
Outcomes from follow-up study on offspring
Death in later life.
Cancer in the reproductive system.
Cancer other than of the reproductive system.
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MRC 1955 (Continued)
Notes UK’s Medical Research Council appointed a conference committee to conduct study.
Report was prepared by DD Reid
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by age and
parity, and simple with an 1:1 allocation ra-
tio. Baseline characteristics in both groups
were similar
Allocation concealment (selection bias) Low risk Sequence was controlled by a central office.
Participants given a series number which
was attached to their clinical record sheet
and bottle of tablets. Treatment tablets,
placebo tablets and packaging were made
identical such that both participant and
personnel would not know which interven-
tion was received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment tablets, placebo tablets and
packaging were made identical such that
both participant and personnel would not
know which intervention was received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Detection bias is low risk since the outcome
is miscarriage. The outcome measurement
is not likely to be influenced by the lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 14 exclusions (10 control, 4 treated) from
entire analysis were explained: 5 miscarried
before commencing intervention, 3 were
non-pregnancies, 2 had advanced beyond
the 16 weeks age criteria, 4 “lacked coop-
eration or some other complication super-
vened”
For the outcomes of miscarriage, there were
no further exclusions
For the outcome of preterm birth, 1 set of
twins was excluded (2 control group)
For the outcome of low birth weight, 1 still-
birth was excluded (treated group) due to
unstated reason
Exclusions in follow-up study of mothers
A total of 136 women were included.
For outcomes of death, genital tract cancer
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MRC 1955 (Continued)
and non-genital tract cancer, 5 exclusions
were due to emigration (1 control), un-
traceable medical records/GP reluctant to
fill out questionnaire /’not traced’ (3 con-
trols, 1 treated)
Exclusions in follow-up study of off-
spring
A total of 136 offspring, including still-
births, were included
For outcomes of genital tract abnormalities
and non-genital tract abnormalities, none
were excluded
At long-term follow-up, 5 were excluded
due to emigration (1 control, 1 treated) and
adoption (1 control, 2 treated)
For outcomes of genital tract cancer and
non-genital tract cancer, 12 were excluded
(same 5 exclusions lost to follow-up, 8
probably due to incomplete questionnaires
from GP). Of the 8, 4 were control, 4 were
treated
Selective reporting (reporting bias) Low risk Protocol not available but all pre-specified
outcomes were reported
Other bias Unclear risk It is probable that 5 women were cross-over
participants whom each had 2 pregnancies
during the original trial. In all 5 cases, their
second pregnancy was allocated to the op-
posite intervention to that of the first preg-
nancy. This is not without concerns of or-
der effects and carry-over effects, but indi-




TIming of randomisation: once pregnancy was confirmed by rising HCG levels from
day 13 to day 15 since oocyte retrieval in IVF
Baseline characteristics in each intervention group were established and deemed compa-
rable
Participants 120 women having undergone IVF-ET were allocated once pregnancy was confirmed
(65 control, 55 intervention)
Age: treatment group mean age was 31.7 +/- 0.7; age range was 25 to 39. Control group
mean age was 32.8 +/- 0.7; age range was 26 to 40
Country: Germany.
Date of study: September 1989, but end time not stated.
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Prietl 1992 (Continued)
Interventions Control group: no hormonal treatment during pregnancy. No placebo was given
Intervention group: intramuscular injection of 500 mg 17α-hydroxyprogesterone
caproate and 10 mg oestradiol valerate in an oily vehicle (Gravibinon) twice a week
Duration: from confirmation of pregnancy until the end of the 12th week of gestation
Outcomes Miscarriage (defined as loss between 7th and 12th week of gestation, confirmed by
ultrasound and decrease in HCG)
Notes Sources of funding: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Allocation sequence was by year of birth.
However, baseline characteristics in each
intervention group were established and
deemed comparable
Allocation concealment (selection bias) High risk Sequence known to personnel.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo was given.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Detection bias is low risk since the outcome
is miscarriage. The outcome measurement
is not likely to be influenced by the lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants (1 control, 1 treated) were
excluded due to ectopic pregnancies
Selective reporting (reporting bias) Low risk Protocol not available but all pre-specified
outcomes were reported
Other bias Unclear risk Sources of funding not stated.
HCG: human chorionic gonadotropin
IVF-ET: in-vitro fertilisation and embryo transfer
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berle 1977 This study was about treating established threatened miscarriage, rather than the prevention of miscarriage
Crowder 1950 This study was about treating established threatened miscarriage, rather than the prevention of miscarriage. This
study randomised before accurate eligibility assessment, leading to the exclusion of over 20% of randomised
participants. This study compared oestrogen and standard treatment versus standard treatment only. Although
some in the oestrogen group also received progesterone, the criteria of selection for such added progesterone
was not mentioned. Progesterone dosage was low (30 mg/day) and duration was short (hospitalisation period)
whereas oestrogen use continued until the 28th week, hence the authors considered the progesterone component
negligible
Lightman 1999 This study introduced intervention prior to established pregnancy. This study did not have a placebo/no
treatment group. This study compared intramuscular progesterone and oestrogen versus vaginal progesterone
and oestrogen
Sathanandan 1991 This study introduced intervention prior to established pregnancy. This study was semi-randomised and did
not assess any of our specified outcomes
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D A T A A N D A N A L Y S E S
Comparison 1. Combined oestrogen and progestogen (other than progesterone) versus placebo




participants Statistical method Effect size
1 Miscarriage 1 148 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.32, 2.80]
2 Perinatal death 1 136 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.53, 1.69]
3 Preterm birth (less than 34 weeks
of gestation)
1 134 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.04]
4 Low birthweight of less than
2500 g
1 136 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.43, 1.77]
5 Genital abnormalities in
offspring
1 136 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.60, 4.08]
6 Abnormalities other than of the
genital tract in offspring
1 136 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.14, 1.30]
7 Cancer in the reproductive
system in offspring
1 136 Risk Ratio (M-H, Random, 95% CI) 2.83 [0.12, 68.29]
8 Cancer other than of the
reproductive system in
offspring
1 136 Risk Ratio (M-H, Random, 95% CI) 2.83 [0.12, 68.29]
9 Cancer in the reproductive
system in mothers
1 156 Risk Ratio (M-H, Random, 95% CI) 6.65 [1.56, 28.29]
10 Cancer other than of the
reproductive system in mothers
1 156 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.36, 10.07]
Comparison 2. Combined oestrogen and progesterone versus no hormonal treatment




participants Statistical method Effect size
1 Miscarriage 1 118 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.23, 1.85]
C O N T R I B U T I O N S O F A U T H O R S
Danforn Lim (DL) is guarantor for the review and developed the concept of topic. The topic was conceived by LC and FW. DL and
KH completed the independent assessment of studies for inclusion, assessment of trial quality and data extraction. DL, LC, and KH
were involved in developing the protocol and final review. All authors reviewed the final version. LC provided a methodological and
statistical perspective and FW provided a clinical perspective.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Two changes were made from the protocol. In this review, we changed the criteria for included studies so that quasi-randomised trials
were included, but in keeping with the protocol, any quasi-randomised trial included was labelled as high risk of bias in its sequence
generation. The second change from our original protocol was that search strategies in OLDMEDLINE, MEDLINE, Embase Classic
and Embase were based upon results that started from an earlier year of publication. This change reflected the newly default ranges of
publication dates set within the mentioned databases. Nonetheless, since earlier dates were used in our searches we can only be more
confident that more literature was reviewed rather than less.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abortion, Spontaneous [∗prevention & control]; Diethylstilbestrol [administration & dosage]; Drug Combinations; Estrogens
[∗administration & dosage]; Ethisterone [administration & dosage]; Fertilization in Vitro; Progesterone [∗administration & dosage];
Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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